EVDI — APOTEX, approved 2026-05-01 (NDA220837).
2,236 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.